Evaluate INMB stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in INMB? | Glauxie AI

Q: What are the risks of investing in INMB?

INmune Bio, Inc. (INMB) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO David J. Moss. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product... Employees: 2,000.

Q: How much debt does INMB have?

Review INMB total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is INMB a good long-term investment?

Evaluate INMB as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in INMB?

🦉

INmune Bio, Inc. (INMB)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEODavid J. Moss

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its...

Key Executives

Name	Title
Cory Randall Ellspermann	Interim Chief Financial Officer
Daniel Frederick Carlson	Head of Investor Relations
David J. Moss	President, Chief Executive Officer, Treasurer, Secretary & Director
Joshua S. Schoonover	General Counsel
Mark William Lowdell	Chief Scientific Officer & Chief Manufacturing Officer

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

INMB Profile Financials

Is INMB stock safe? How much debt does INMB have? Is INMB a good long-term investment?